Transitional cell carcinoma (TCC) of the bladder is the most common urinary tract tumour in dogs, causing progressive urinary obstruction and significant welfare harm with limited curative options but good palliative responses.
Bladder TCC causes welfare harm primarily through urinary obstruction — the progressive difficulty and pain of attempted urination as the tumour grows. Dogs with urethral obstruction from TCC are in significant pain, showing prolonged straining, crying during urination attempts, and eventually complete inability to urinate — a life-threatening emergency. Palliative management with piroxicam achieves disease stabilisation in the majority of dogs, reducing tumour growth and inflammation, which meaningfully extends comfortable life. The welfare goal in TCC management is not cure — which is rarely achievable — but maintenance of comfortable urination and quality of life for as long as possible. Urethral stent placement can provide rapid relief of obstruction and is appropriate when tumour growth causes acute retention. Monitoring urination quality at home — the owner observing the dog's comfort during voiding — provides better real-time welfare information than tumour size measurements. Proactive quality-of-life assessment using validated scales ensures that palliative treatment serves the dog's comfort rather than extending life at the cost of suffering.